Bariatric surgery as an important step towards kidney transplantation in patients with morbid obesity and chronic kidney disease
- 作者: Voronets E.M.1, Smirnov A.V.1, Stankevich V.R.1, Abdulkerimov Z.A.2, Panchenkov D.N.1,2, Sharobaro V.I.3, Ivanov Y.V.1,2
-
隶属关系:
- Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
- Russian University of Medicine
- Smolensk State Medical University
- 期: 卷 31, 编号 1 (2025)
- 页面: 61-67
- 栏目: Reviews
- ##submission.dateSubmitted##: 21.08.2024
- ##submission.dateAccepted##: 22.12.2024
- ##submission.datePublished##: 17.02.2025
- URL: https://medjrf.com/0869-2106/article/view/635327
- DOI: https://doi.org/10.17816/medjrf635327
- ID: 635327
如何引用文章
详细
An analysis of scientific studies devoted to the problem of bariatric surgery in patients with stages IIIb–V as chronic kidney disease (CKD) as the main step towardspossible kidney transplantation is presented. Obesity leads to CKD both directly, acting as an independent risk factor, and indirectly, by increasing the risk of diabetes, hypertension and atherosclerosis (i.e., a group of independent risk factors for CKD). CKD with an outcome of chronic renal failure is the second most common cause of mortality and disability in obese patients. In most kidney transplantation centers, a body mass index of more than 40 kg/m2 is a contraindication for to transplantation (refusal to be included on the waiting list); and a body mass index of more than 35 kg/m2 is a relative contraindication. In some cases, bariatric surgery is the only way to perform organ transplantation. Direct indications for bariatric surgery in patients with morbid obesity undergoing hemodialysis therapy have been identified. The established diet before/after bariatric surgery with the inclusion of protein isolate is not the cause of protein overload in patients with CKD. Bariatric surgery is considered a safe treatment option for obesity in potential kidney transplant candidates, given their continued need for immunosuppressive therapy.
全文:

作者简介
Evgenia Voronets
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
编辑信件的主要联系方式.
Email: zhenuaria@list.ru
ORCID iD: 0009-0003-5546-8671
俄罗斯联邦, Moscow
Alexander Smirnov
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Email: alvsmirnov@mail.ru
ORCID iD: 0000-0003-3897-8306
SPIN 代码: 5619-1151
MD, Cand. Sci. (Medicine), Associate Professor
俄罗斯联邦, MoscowVladimir Stankevich
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Email: v-stankevich@yandex.ru
ORCID iD: 0000-0002-8620-8755
SPIN 代码: 5126-6092
MD, Cand. Sci. (Medicine)
俄罗斯联邦, MoscowZaypulla Abdulkerimov
Russian University of Medicine
Email: dr-zay@yandex.ru
ORCID iD: 0000-0003-4555-5184
SPIN 代码: 7022-2259
MD, Cand. Sci. (Medicine)
俄罗斯联邦, MoscowDmitry Panchenkov
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies; Russian University of Medicine
Email: dnpanchenkov@mail.ru
ORCID iD: 0000-0001-8539-4392
SPIN 代码: 4316-4651
MD, Dr. Sci. (Medicine), Professor
俄罗斯联邦, Moscow; MoscowVladimir Sharobaro
Smolensk State Medical University
Email: sharobarovi1@mail.ru
ORCID iD: 0000-0003-1501-706X
SPIN 代码: 8529-5855
MD, Dr. Sci. (Medicine), Assistant Professor
俄罗斯联邦, SmolenskYury Ivanov
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies; Russian University of Medicine
Email: ivanovkb83@yandex.ru
ORCID iD: 0000-0001-6209-4194
SPIN 代码: 3240-4335
MD, Dr. Sci. (Medicine), Professor
俄罗斯联邦, Moscow; Moscow参考
- Di Cesare M, Bentham J, Zhou B, et al. Trends in adult bodymass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377–1396. doi: 10.1016/S0140-6736(16)30054-X EDN: WSVMWT Erratum in: Lancet. 2016;387(10032):1998. doi: 10.1016/S0140-6736(16)30472-X
- Rutkowski P, Klassen A, Sebekova K, et al. Renal disease in obesity: the need for greater attention. J Ren Nutr. 2006;16(3):216–223. doi: 10.1053/j.jrn.2006.04.017
- Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375–C391. doi: 10.1152/ajpcell.00379.2020 EDN: KGYKVH
- Hall JE, do Carmo JM, da Silva AA, et al. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019;15(6):367–385. doi: 10.1038/s41581-019-0145-4 EDN: UIPTZA
- Czaja-Stolc S, Potrykus M, Stankiewicz M, et al. Pro-inflammatory profile of adipokines in obesity contributes to pathogenesis, nutritional disorders, and cardiovascular risk in chronic kidney disease. Nutrients. 2022;14(7):1457. doi: 10.3390/nu14071457 EDN: USBZEK
- Martin-Taboada M, Vila-Bedmar R, Medina-Gómez G. From obesity to chronic kidney disease: how can adipose tissue affect renal function? Nephron. 2021;145(6):609–613. doi: 10.1159/000515418 EDN: NXFKTR
- Garofalo C, Borrelli S, Minutolo R, et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91(5):1224–1235. doi: 10.1016/j.kint.2016.12.013 EDN: YXQYCZ
- Panwar B, Hanks LJ, Tanner RM, et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int. 2015;87(6):1216–1222. doi: 10.1038/ki.2014.384
- Jung CH, Lee MJ, Kang YM, et al. The risk of chronic kidney disease in a metabolically healthy obese population. Kidney Int. 2015;88(4):843–850. doi: 10.1038/ki.2015.183
- Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–28. doi: 10.7326/0003-4819-144-1-200601030-00006
- Hojs R, Ekart R, Bevc S, Vodošek Hojs N. Chronic kidney disease and obesity. Nephron. 2023;147(11):660–664. doi: 10.1159/000531379 EDN: GTILBX
- Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am. 2003;32(4):741–vii. doi: 10.1016/s0889-8529(03)00074-4
- Jiang Z, Wang Y, Zhao X, et al. Obesity and chronic kidney disease. Am J Physiol Endocrinol Metab. 2023;324(1):E24–E41. doi: 10.1152/ajpendo.00179.2022 EDN: MJNLDS
- Martínez-Montoro JI, Morales E, Cornejo-Pareja I, et al. Obesity-related glomerulopathy: Current approaches and future perspectives. Obes Rev. 2022;23(7):e13450. doi: 10.1111/obr.13450 EDN: AWTVBA
- Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–298. doi: 10.1038/s41574-019-0176-8 EDN: PYTWYS
- Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19–33. doi: 10.1038/sj.ki.5002586
- D'Agati VD, Chagnac A, de Vries AP, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12(8):453–471. doi: 10.1038/nrneph.2016.75 EDN: WRLYVT
- Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12(6):1211–1217. doi: 10.1681/ASN.V1261211
- Dudley C, Harden P. Renal Association Clinical Practice Guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract. 2011;118 Suppl. 1:c209–c224. doi: 10.1159/000328070
- Segev DL, Simpkins CE, Thompson RE, et al. Obesity impacts access to kidney transplantation. J Am Soc Nephrol. 2008;19(2):349–355. doi: 10.1681/ASN.2007050610
- Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6(2):357–363. doi: 10.1111/j.1600-6143.2005.01198.x
- Chang JH, Mushailov V, Mohan S. Obesity and kidney transplantation. Curr Opin Organ Transplant. 2023;28(2):149–155. doi: 10.1097/MOT.0000000000001050 EDN: HBKUOY
- Hill CJ, Courtney AE, Cardwell CR, et al. Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015;30(8):1403–1411. doi: 10.1093/ndt/gfv214
- Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104(4S1 Suppl. 1):S11–S103. doi: 10.1097/TP.0000000000003136 EDN: IOHQKX
- Clinical guidelines. Living kidney donation. Russian Transplantation Society; 2023.
- Zharikov AA, Saydulaev DA, Sadovnikov SV, Miloserdov IA. Efficacy of surgical techniques for morbid obesity and their potentials in end-stage renal disease in preparation for kidney transplantation. Russian Journal of Transplantology and Artificial Organs. 2022;24(2):125–133. doi: 10.15825/1995-1191-2022-2-125-133 EDN: ZJSHAX
- Fischer H, Weiss RE, Friedman AN, et al. The relationship between kidney function and body mass index before and after bariatric surgery in patients with chronic kidney disease. Surg Obes Relat Dis. 2021;17(3):508–515. doi: 10.1016/j.soard.2020.11.010 EDN: ZHTGLQ
- Chang AR, Grams ME, Navaneethan SD. Bariatric surgery and kidney-related outcomes. Kidney Int Rep. 2017;2(2):261–270. doi: 10.1016/j.ekir.2017.01.010 EDN: YHMSYH
- Coleman KJ, Shu YH, Fischer H, et al. Bariatric surgery and risk of death in persons with chronic kidney disease. Ann Surg. 2022;276(6):e784–e791. doi: 10.1097/SLA.0000000000004851 EDN: CPHUUD
- Pané A, Claro M, Molina-Andujar A, et al. Bariatric surgery outcomes in patients with chronic kidney disease. J Clin Med. 2023;12(18):6095. doi: 10.3390/jcm12186095 EDN: XKPZHB
- Friedman AN, Cohen RV. Bariatric surgery as a renoprotective intervention. Curr Opin Nephrol Hypertens. 2019;28(6):537–544. doi: 10.1097/MNH.0000000000000539
- Holcomb CN, Goss LE, Almehmi A, et al. Bariatric surgery is associated with renal function improvement. Surg Endosc. 2018;32(1):276–281. doi: 10.1007/s00464-017-5674-y EDN: FWNPLP
- Imam TH, Coleman KJ. Obesity and mortality in end-stage renal disease. is it time to reverse the "reverse epidemiology" — at least in peritoneal dialysis? J Ren Nutr. 2019;29(4):269–275. doi: 10.1053/j.jrn.2018.09.005
- Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg. 2014;24(1):42–55. doi: 10.1007/s11695-013-1079-8 EDN: SKLLDB
- Stankevich VR, Ivanov YuV, Sharobaro VI, et al. Surgical treatment of morbid obesity. Moscow: Redprint; 2021. 292 p. (In Russ.)
- Clinical recommendations. Chronic kidney disease (CKD). Association of nephrologists. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2021.
- Kostro JZ, Bzoma B, Proczko-Stepaniak M, et al. Kidney transplantation in patients after bariatric surgery: high-volume bariatric and transplant center experience. Transplant Proc. 2022;54(4):955–959. doi: 10.1016/j.transproceed.2022.03.014 EDN: ULNUPK
- Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50. doi: 10.1111/j.1467-789X.2009.00614.x
- Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215–231. doi: 10.2165/00003088-200039030-00004 EDN: XWGENS
- Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant. 1996;10(5):414–419.
- Rogers CC, Alloway RR, Alexander JW, et al. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008;22(3):281–291. doi: 10.1111/j.1399-0012.2007.00783.x
- Gheith O, Al-Otaibi T, Halim MA, et al. Bariatric surgery in renal transplant patients. Exp Clin Transplant. 2017;15(Suppl. 1):164–169. doi: 10.6002/ect.mesot2016.P35
- Hardinger KL, Park JM, Schnitzler MA, et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant. 2004;4(4):621–625. doi: 10.1111/j.1600-6143.2004.00383.x
- Baraldo M, Furlanut M. Chronopharmacokinetics of ciclosporin and tacrolimus. Clin Pharmacokinet. 2006;45(8):775–788. doi: 10.2165/00003088-200645080-00002 EDN: BHMERZ
- Tan SYT, Lee PC, Ganguly S, et al. Bariatric Surgery in kidney transplant candidates and recipients: experience at an Asian center. J Obes Metab Syndr. 2022;31(4):325–333. doi: 10.7570/jomes21090 EDN: GGQKYN
- Maroun J, Vahibe A, Shah M, et al. Impact of chronic immunosuppression on short-, mid-, and long-term bariatric surgery outcomes. Obes Surg. 2023;33(1):240–246. doi: 10.1007/s11695-022-06372-7 EDN: QZIVBI
- Reding R, Michel LA, Donckier J, et al. Surgery in patients on long-term steroid therapy: a tentative model for risk assessment. Br J Surg. 1990;77(10):1175–1178. doi: 10.1002/bjs.1800771028
- Hoogeveen EK, Aalten J, Rothman KJ, et al. Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation. 2011;91(8):869–874. doi: 10.1097/TP.0b013e3182100f3a
- Yemini R, Nesher E, Carmeli I, et al. Bariatric surgery is efficacious and improves access to transplantation for morbidly obese renal transplant candidates. Obes Surg. 2019;29(8):2373–2380. doi: 10.1007/s11695-019-03925-1 EDN: GWRSAA
- Cohen JB, Lim MA, Tewksbury CM, et al. Bariatric surgery before and after kidney transplantation: long-term weight loss and allograft outcomes. Surg Obes Relat Dis. 2019;15(6):935–941. doi: 10.1016/j.soard.2019.04.002
补充文件
